These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 34622433)

  • 1. Low-dose ticagrelor with or without acetylsalicylic acid in patients with acute coronary syndrome: Rationale and design of the ELECTRA-SIRIO 2 trial.
    Kubica J; Adamski P; Gorog DA; Kubica A; Jilma B; Budaj A; Siller-Matula JM; Gurbel PA; Alexopoulos D; Badarienė J; Dąbrowski P; Dudek D; Giannitsis E; Horszczaruk G; Jaguszewski MJ; James S; Jeong YH; Kryjak M; Niezgoda P; Ostrowska M; Patti G; Romanek J; Di Somma S; Specchia G; Tantry U; Gąsior M; Tycińska A; Wojakowski W; Buszko K; Gil R; Gruchała M; Kasprzak J; Kleinrok A; Legutko J; Lesiak M; Navarese EP
    Cardiol J; 2022; 29(1):148-153. PubMed ID: 34622433
    [No Abstract]   [Full Text] [Related]  

  • 2. ANalgesic Efficacy and safety of MOrphiNe versus methoxyflurane in patients with acute myocardial infarction: the rationale and design of the ANEMON-SIRIO 3 study: a multicentre, open-label, phase II, randomised clinical trial.
    Kubica A; Kosobucka A; Niezgoda P; Adamski P; Buszko K; Lesiak M; Wojakowski W; Gasior M; Gorący J; Kleinrok A; Nadolny K; Navarese E; Kubica J
    BMJ Open; 2021 Mar; 11(3):e043330. PubMed ID: 33649058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new approach to ticagrelor-based de-escalation of antiplatelet therapy after acute coronary syndrome. A rationale for a randomized, double-blind, placebo-controlled, investigator-initiated, multicenter clinical study.
    Kubica J; Adamski P; Niezgoda P; Kubica A; Podhajski P; Barańska M; Umińska JM; Pietrzykowski Ł; Ostrowska M; Siller-Matula JM; Badarienė J; Bartuś S; Budaj A; Dobrzycki S; Fidor Ł; Gąsior M; Gessek J; Gierlotka M; Gil R; Gorący J; Grzelakowski P; Hajdukiewicz T; Jaguszewski M; Janion M; Kasprzak J; Kern A; Klecha A; Kleinrok A; Kochman W; Krakowiak B; Legutko J; Lesiak M; Nosal M; Piotrowski G; Przybylski A; Roleder T; Skonieczny G; Sobieszek G; Tycińska A; Wojciechowski D; Wojakowski W; Wójcik J; Zielińska M; Żurakowski A; Specchia G; Gorog DA; Navarese EP
    Cardiol J; 2021; 28(4):607-614. PubMed ID: 34096012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benefit and Risks of Aspirin in Addition to Ticagrelor in Acute Coronary Syndromes: A Post Hoc Analysis of the Randomized GLOBAL LEADERS Trial.
    Tomaniak M; Chichareon P; Onuma Y; Deliargyris EN; Takahashi K; Kogame N; Modolo R; Chang CC; Rademaker-Havinga T; Storey RF; Dangas GD; Bhatt DL; Angiolillo DJ; Hamm C; Valgimigli M; Windecker S; Steg PG; Vranckx P; Serruys PW;
    JAMA Cardiol; 2019 Nov; 4(11):1092-1101. PubMed ID: 31557763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum uric acid levels during dual antiplatelet therapy with ticagrelor or clopidogrel: Results from a single-centre study.
    Nardin M; Verdoia M; Pergolini P; Rolla R; Barbieri L; Schaffer A; Marino P; Bellomo G; Suryapranata H; De Luca G;
    Nutr Metab Cardiovasc Dis; 2016 Jul; 26(7):567-574. PubMed ID: 27134063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ticagrelor Monotherapy Versus Ticagrelor With Aspirin in Acute Coronary Syndrome Patients With a High Risk of Ischemic Events.
    Lee SJ; Lee YJ; Kim BK; Hong SJ; Ahn CM; Kim JS; Ko YG; Choi D; Hong MK; Jang Y
    Circ Cardiovasc Interv; 2021 Aug; 14(8):e010812. PubMed ID: 34281363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ticagrelor monotherapy following percutaneous coronary intervention for acute coronary syndrome in TWILIGHT patients: still a future for aspirin?
    Lunardi M; Onuma Y; Serruys PW
    Eur Heart J; 2021 Jul; 42(27):2708-2709. PubMed ID: 33501975
    [No Abstract]   [Full Text] [Related]  

  • 8. Sex Differences in Outcomes of Ticagrelor Therapy With or Without Aspirin After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome: A Post Hoc Secondary Analysis of the TICO Randomized Clinical Trial.
    Lee B; Lee SJ; Kim BK; Lee YJ; Hong SJ; Ahn CM; Kim JS; Ko YG; Choi D; Hong MK; Jang Y
    Arterioscler Thromb Vasc Biol; 2023 Jun; 43(6):e218-e226. PubMed ID: 37021576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary Syndrome: The TICO Randomized Clinical Trial.
    Kim BK; Hong SJ; Cho YH; Yun KH; Kim YH; Suh Y; Cho JY; Her AY; Cho S; Jeon DW; Yoo SY; Cho DK; Hong BK; Kwon H; Ahn CM; Shin DH; Nam CM; Kim JS; Ko YG; Choi D; Hong MK; Jang Y;
    JAMA; 2020 Jun; 323(23):2407-2416. PubMed ID: 32543684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiplatelet effect of ticagrelor compared to tirofiban in non-ST-segment elevation ACS patients undergoing PCI. The result of the TE-CLOT trial.
    Kim JS; Han DC; Jeong YH; Park DW; Sohn CB; Hwang KW; Lee SH; Choi JH; Chon MK; Lee SY; Hwang J; Kim IS; Lee SM; Han J; Noh M; Kim CH; Chun KJ; Park YH; Kim JH
    Thromb Haemost; 2016 Jan; 115(1):213-21. PubMed ID: 26581884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of one-month versus twelve-month dual antiplatelet therapy after implantation of drug-eluting stents guided by either intravascular ultrasound or angiography in patients with acute coronary syndrome: rationale and design of prospective, multicenter, randomized, controlled IVUS-ACS and ULTIMATE-DAPT trial.
    Ge Z; Gao XF; Kan J; Kong XQ; Zuo GF; Ye F; Tian NL; Lin S; Liu ZZ; Shao YB; He YQ; Wen SY; Yang Q; Xia Y; Wang ZZ; Xiao PX; Li F; Zeng HS; Yang S; Wang Y; Tao L; Gao DS; Qu H; Qian XS; Han YL; Chen F; Zhang JJ; Chen SL
    Am Heart J; 2021 Jun; 236():49-58. PubMed ID: 33621541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long versus short dual antiplatelet therapy in acute coronary syndrome patients treated with prasugrel or ticagrelor and coronary revascularization: Insights from the RENAMI registry.
    D'Ascenzo F; Bertaina M; Fioravanti F; Bongiovanni F; Raposeiras-Roubin S; Abu-Assi E; Kinnaird T; Ariza-Solé A; Manzano-Fernández S; Templin C; Velicki L; Xanthopoulou I; Cerrato E; Rognoni A; Boccuzzi G; Omedè P; Montabone A; Taha S; Durante A; Gili S; Magnani G; Autelli M; Grosso A; Blanco PF; Garay A; Quadri G; Varbella F; Queija BC; Paz RC; Fernández MC; Pousa IM; Gallo D; Morbiducci U; Dominguez-Rodriguez A; Valdés M; Cequier A; Alexopoulos D; Iñiguez-Romo A; Gaita F; Rinaldi M; Lüscher TF
    Eur J Prev Cardiol; 2020 May; 27(7):696-705. PubMed ID: 30862233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multi-Omics Signatures Link to Ticagrelor Effects on Vascular Function in Patients With Acute Coronary Syndrome.
    Tam CF; Chan YH; Wong YK; Li Z; Zhu X; Su KJ; Ganguly A; Hwa K; Ling XB; Tse HF
    Arterioscler Thromb Vasc Biol; 2022 Jun; 42(6):789-798. PubMed ID: 35387483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vitamin D levels and platelet reactivity in diabetic patients receiving dual antiplatelet therapy.
    Verdoia M; Pergolini P; Nardin M; Rolla R; Negro F; Kedhi E; Suryapranata H; Marcolongo M; Carriero A; De Luca G;
    Vascul Pharmacol; 2019 Sep; 120():106564. PubMed ID: 31176855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT study.
    Baber U; Dangas G; Cohen DJ; Gibson CM; Mehta SR; Angiolillo DJ; Pocock SJ; Krucoff MW; Kastrati A; Ohman EM; Steg PG; Badimon J; Zafar MU; Chandrasekhar J; Sartori S; Aquino M; Mehran R
    Am Heart J; 2016 Dec; 182():125-134. PubMed ID: 27914492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of Crushed Ticagrelor Versus Eptifibatide Bolus Plus Clopidogrel in Troponin-Negative Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention: A Randomized Clinical Trial.
    Marian MJ; Abu Daya H; Chatterjee A; Al Solaiman F; Sasse MF; Fonbah WS; Workman RW; Johnson BE; Carlson SE; Brott BC; Prabhu SD; Leesar MA
    J Am Heart Assoc; 2019 Dec; 8(23):e012844. PubMed ID: 31766977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ticagrelor or Prasugrel in Patients With Acute Coronary Syndrome Undergoing Complex Percutaneous Coronary Intervention.
    Coughlan JJ; Aytekin A; Ndrepepa G; Schüpke S; Bernlochner I; Mayer K; Neumann FJ; Menichelli M; Richardt G; Wöhrle J; Witzenbichler B; Gewalt S; Xhepa E; Kufner S; Sager HB; Joner M; Ibrahim T; Fusaro M; Laugwitz KL; Schunkert H; Kastrati A; Cassese S
    Circ Cardiovasc Interv; 2021 Jul; 14(7):e010565. PubMed ID: 34130477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Homocysteine levels and platelet reactivity in coronary artery disease patients treated with ticagrelor.
    Verdoia M; Rolla R; Negro F; Tonon F; Pergolini P; Nardin M; Marcolongo M; De Luca G;
    Nutr Metab Cardiovasc Dis; 2020 Feb; 30(2):292-299. PubMed ID: 31780401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacodynamic Comparison of Ticagrelor Monotherapy Versus Ticagrelor and Aspirin in Patients After Percutaneous Coronary Intervention: The TEMPLATE (Ticagrelor Monotherapy and Platelet Reactivity) Randomized Controlled Trial.
    Johnson TW; Baos S; Collett L; Hutchinson JL; Nkau M; Molina M; Aungraheeta R; Reilly-Stitt C; Bowles R; Reeves BC; Rogers CA; Mundell SJ; Baumbach A; Mumford AD
    J Am Heart Assoc; 2020 Dec; 9(24):e016495. PubMed ID: 33305660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Parathyroid Hormone Levels and High-Residual Platelet Reactivity in Patients Receiving Dual Antiplatelet Therapy With Acetylsalicylic Acid and Clopidogrel or Ticagrelor.
    Verdoia M; Pergolini P; Rolla R; Nardin M; Barbieri L; Schaffer A; Bellomo G; Marino P; Suryapranata H; De Luca G;
    Cardiovasc Ther; 2016 Aug; 34(4):209-15. PubMed ID: 27086085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.